Switzerland / Netherlands / Italy / Sweden / United States / Korea / Spain / /
Currency
USD / / /
Event
FDA Phase / /
Facility
National Institute of Allergy / /
IndustryTerm
potential pharmaceutical / appropriate health technologies / potent vaccine delivery systems / biotechnology partners / biopharmaceutical production technology / manufacturing platform / biopharmaceutical industry / technology lie / biopharmaceutical / recombinant malaria vaccine / vaccine technology / biopharmaceutical products / production technology / travel vaccines / /
MedicalCondition
investigational malaria / common cold / deadliest malaria / mild respiratory infections / hepatitis B / malaria Malaria / severe illness / important childhood diseases / illness / prevalent infections / influenza / communicable diseases / disease / malaria / recombinant malaria / complicated malaria / highly efficacious malaria / infectious diseases / P. falciparum malaria / oral cholera / only aluminium-free hepatitis A / /
MedicalTreatment
vaccination / /
Organization
USAID MVDP / US Securities and Exchange Commission / Melinda Gates Foundation / National Institute of Allergy and Infectious Diseases / United States Agency for International Development / Division of Infectious Diseases / PATH / USAID Global Health Bureau / office of Health / Nutrition / and Infectious Diseases / /
Person
Christian Loucq / Jaap Goudsmit / Carter Diggs / / /
Position
Chief Scientific Officer / Director / Oya Yavuz Vice President Corporate Communications & Investor Relations Tel. / /
Product
malaria vaccine / /
Region
sub-Saharan Africa / /
Technology
biopharmaceutical production technology / antibodies / biotechnology / conventional production technologies / vaccine technology / production technology / appropriate health technologies / /
For more information, contact: The PATH Malaria Vaccine Initiative Preeti Singh +extor